Pancreatic cancer
Conditions
Interventions
experimental group:laparoscopic pancreatectomy
control group:open pancreatectomy
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients confirmed resectable or borderline resectable pancreatic adenocarcinoma after neoadjuvant chemotherapy follow 2020 V1 NCCN; 2. Patients aged 18 to 80 years, regardless of gender; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; 4. The expected postoperative survival >= 3 months; 5. Ability to comply with research plans and other program requirements; 6. Volunteer to be the subject and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients have contraindication to surgery; 2. Patients confirmed locally advanced or unresectable pancreatic cancer after neoadjuvant chemotherapy (refer to 2020.V1 version of NCCN Pancreatic Cancer Guidelines); 3. Imaging studies found distant metastases; 4. Patients with severe impairment of cardiacliver or kidney function (Cardiac function grade 3-4, ALT or AST exceeds 5 times the upper limit of normal value, Creatinine exceeds the upper limit of normal); 5. Pregnant or lactating female patients; 6. Patients with other malignant tumors or hematological diseases; 7. Patients have participanted in other clinical trials of pancreatic cancer within three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-free survival;R0 resection rate;operative duration;number of lymph node dissection;major postoperative complications;minor postoperative complications;length of postoperative hospital stay;length of postoperative ICU stay;intraoperative blood loss;90-day mortality; | — |
Countries
China
Contacts
Public ContactBing Peng
West China Hospital of Sichuan University
Outcome results
None listed